Q3 Earnings Forecast for ASND Issued By HC Wainwright

Posted by George Bondi on Sep 1st, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for Ascendis Pharma A/S in a report released on Thursday, August 27th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings of $1.16 per share for the quarter. HC Wainwright has a “Buy” rating and a $345.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.90 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S’s Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $3.93 EPS, Q1 2027 earnings at $1.76 EPS, Q2 2027 earnings at $2.48 EPS, Q3 2027 earnings at $3.20 EPS, Q4 2027 earnings at $4.42 EPS and FY2027 earnings at $11.88 EPS.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The company had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million.

A number of other analysts have also commented on ASND. Barclays reduced their price objective on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Oppenheimer restated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Wells Fargo & Company decreased their price objective on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Morgan Stanley lifted their price objective on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Buy” and an average target price of $304.95.

Read Our Latest Stock Analysis on ASND

Ascendis Pharma A/S Trading Up 6.1%

Shares of ASND opened at $263.04 on Monday. The business’s 50-day moving average price is $256.44 and its 200 day moving average price is $239.47. The stock has a market capitalization of $16.41 billion, a P/E ratio of 20.41 and a beta of 0.39. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in shares of Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after buying an additional 880,836 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after acquiring an additional 450,000 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 29.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after acquiring an additional 232,730 shares in the last quarter. Vestal Point Capital LP boosted its position in Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after purchasing an additional 400,000 shares during the last quarter. Finally, FIL Ltd boosted its position in Ascendis Pharma A/S by 4.2% during the fourth quarter. FIL Ltd now owns 478,641 shares of the biotechnology company’s stock valued at $102,065,000 after purchasing an additional 19,301 shares during the last quarter.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime purchased 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the acquisition, the director owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 40.00% of the company’s stock.

About Ascendis Pharma A/S

(Get Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.